Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
TERN - Terns Pharmaceuticals, Inc.
Market Cap 408.66M P/E - EPS this Y -0.80% Ern Qtrly Grth -
Income -95.89M Forward P/E -5.11 EPS next Y -7.80% 50D Avg Chg -25.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg -22.00%
Dividend N/A Price/Book 1.42 EPS next 5Y - 52W High Chg -49.00%
Recommedations 2.10 Quick Ratio 20.57 Shares Outstanding 84.44M 52W Low Chg 276.00%
Insider Own 0.14% ROA -25.99% Shares Float 49.25M Beta -0.38
Inst Own 84.33% ROE -38.92% Shares Shorted/Prior 3.76M/1.80M Price 7.21
Gross Margin - Profit Margin - Avg. Volume 850,187 Target Price 18.92
Oper. Margin - Earnings Date Nov 12 Volume 280,719 Change 0.42%
Healthcare | Biotechnology | United States
About Terns Pharmaceuticals, Inc.

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of MASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.

Terns Pharmaceuticals, Inc. News
12/16/24 Is Terns Pharmaceuticals, Inc. (TERN) the Best Weight Loss Stock to Buy Now According to Hedge Funds?
12/11/24 Terns Pharmaceuticals CEO & Director Acquires 423% More Stock
12/03/24 Terns Pharmaceuticals Announces Positive Early Data from Phase 1 CARDINAL Trial of TERN-701 for Chronic Myeloid Leukemia
12/02/24 Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)
11/18/24 Terns Pharmaceuticals Appoints Heather Turner, J.D., to Board of Directors
11/14/24 We Think Terns Pharmaceuticals (NASDAQ:TERN) Can Afford To Drive Business Growth
11/12/24 Terns Pharmaceuticals Reports Third Quarter 2024 Financial Results and Corporate Updates
11/06/24 Terns Pharmaceuticals to Participate in Upcoming November Investor Conferences
09/24/24 Insiders Snap Up These 2 ‘Strong Buy’ Stocks
09/18/24 This Small-Cap Stock Has a Promising GLP-1 Drug That Could Rival Novo Nordisk's and Eli Lilly's Weight Loss Treatments
09/17/24 OrbiMed Advisors LLC Increases Stake in Terns Pharmaceuticals Inc
09/16/24 With 55% ownership, Terns Pharmaceuticals, Inc. (NASDAQ:TERN) boasts of strong institutional backing
09/15/24 Missed Out on Viking Therapeutics? Buy This Weight Loss Biotech Stock Right Now.
09/15/24 Should You Invest in This Under-the-Radar Weight Loss Stock?
09/14/24 1 New Weight Loss Drug Stock to Buy Now With $1,000 and Hold for 5 Years or More
09/12/24 Terns Announces Closing of Public Offering of Shares of Common Stock and Pre-Funded Warrants, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
09/12/24 Biotech Stock Roundup: TERN, SMMT Stocks Surge on Study Data, GSK's Vaccine Study Fails & More
09/10/24 Terns Announces Pricing of Upsized $150.15 Million Public Offering
09/10/24 Terns Stock Soars on Positive Data From Phase I Study of Obesity Drug
09/10/24 Terns Pharmaceuticals reports positive data from Phase I trial of obesity treatment
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Yoon Seokho Bryan COO and General Coun.. COO and General Counsel Nov 30 Buy 3.78 743 2,809 18,399 12/04/23
Vignola Mark J. Chief Financial Offi.. Chief Financial Officer Nov 30 Buy 3.78 743 2,809 18,399 12/04/23
Yoon Seokho Bryan COO and General Coun.. COO and General Counsel Feb 01 Buy 1.41 3 4 7,659 02/03/23
Vignola Mark J. Chief Financial Offi.. Chief Financial Officer Feb 01 Buy 1.41 3 4 7,659 02/03/23
Sundaram Senthil Vel Chief Executive Offi.. Chief Executive Officer Feb 01 Buy 1.41 3 4 7,659 02/03/23
ORBIMED ADVISORS LLC Director Director Dec 23 Buy 7.25 137,931 1,000,000 4,882,854 12/28/22
GORDON CARL L Director Director Dec 23 Buy 7.25 137,931 1,000,000 4,882,854 12/28/22
Vivo Opportunity, LLC 10% Owner 10% Owner Dec 23 Buy 7.25 758,620 5,499,995 4,340,212 12/23/22
Lu Hongbo Director Director Dec 23 Buy 7.25 758,620 5,499,995 4,340,212 12/23/22
Vivo Opportunity, LLC 10% Owner 10% Owner Sep 07 Buy 3.60 600,000 2,160,000 3,581,592 09/08/22
Lu Hongbo Director Director Sep 07 Buy 3.60 600,000 2,160,000 3,581,592 09/08/22
ORBIMED ADVISORS LLC Director Director Aug 16 Buy 2.42 3,690,000 8,929,800 762,400 08/18/22
GORDON CARL L Director Director Aug 16 Buy 2.42 3,690,000 8,929,800 762,400 08/18/22
Vivo Opportunity, LLC 10% Owner 10% Owner Aug 12 Buy 2.8 2,624,239 7,347,869 2,981,592 08/16/22
Lu Hongbo Director Director Aug 12 Buy 2.8 2,624,239 7,347,869 2,981,592 08/16/22
Yoon Seokho Bryan COO and General Coun.. COO and General Counsel May 31 Buy 1.47 7,656 11,254 7,656 06/08/22
Vignola Mark J. Chief Financial Offi.. Chief Financial Officer May 31 Buy 1.47 7,656 11,254 7,656 06/08/22
Sundaram Senthil Vel Chief Executive Offi.. Chief Executive Officer May 31 Buy 1.47 7,656 11,254 7,656 06/08/22